Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.

Mukherjee S, Wood J, Liaquat I, Stapleton SR, Martin AJ.

Clin Neurol Neurosurg. 2020 Jan;188:105568. doi: 10.1016/j.clineuro.2019.105568. Epub 2019 Oct 24.

PMID:
31739155
2.

Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.

Bloch O, Han SJ, Cha S, Sun MZ, Aghi MK, McDermott MW, Berger MS, Parsa AT.

J Neurosurg. 2012 Dec;117(6):1032-8. doi: 10.3171/2012.9.JNS12504. Epub 2012 Oct 5.

PMID:
23039151
3.

Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?

Pala A, Schmitz AL, Knoll A, Schneider M, Hlavac M, K├Ânig R, Wirtz CR, Coburger J.

Clin Neurol Neurosurg. 2018 Apr;167:6-10. doi: 10.1016/j.clineuro.2018.02.003. Epub 2018 Feb 5.

PMID:
29425743
4.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
5.

Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.

Iaccarino C, Orlandi E, Ruggeri F, Nicoli D, Torricelli F, Maggi M, Cerasti D, Pisanello A, Pedrazzi G, Froio E, Crafa P, D'Abbiero N, Michiara M, Ghadirpour R, Servadei F.

Clin Neurol Neurosurg. 2015 May;132:1-8. doi: 10.1016/j.clineuro.2015.01.029. Epub 2015 Feb 7.

PMID:
25723791
6.

Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery.

Sharma M, Schroeder JL, Elson P, Meola A, Barnett GH, Vogelbaum MA, Suh JH, Chao ST, Mohammadi AM, Stevens GHJ, Murphy ES, Angelov L.

J Neurosurg. 2018 Oct 19;131(2):489-499. doi: 10.3171/2018.4.JNS172909.

PMID:
30485180
7.

Survival and functional status after resection of recurrent glioblastoma multiforme.

Barker FG 2nd, Chang SM, Gutin PH, Malec MK, McDermott MW, Prados MD, Wilson CB.

Neurosurgery. 1998 Apr;42(4):709-20; discussion 720-3.

PMID:
9574634
8.

The relationship between repeat resection and overall survival in patients with glioblastoma: a time-dependent analysis.

Goldman DA, Hovinga K, Reiner AS, Esquenazi Y, Tabar V, Panageas KS.

J Neurosurg. 2018 Nov 1;129(5):1231-1239. doi: 10.3171/2017.6.JNS17393.

9.

Repeat-surgery at Glioblastoma recurrence, when and why to operate?

Ening G, Huynh MT, Schmieder K, Brenke C.

Clin Neurol Neurosurg. 2015 Sep;136:89-94. doi: 10.1016/j.clineuro.2015.05.024. Epub 2015 May 28.

PMID:
26092644
10.

Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.

Woo PYM, Ho JMK, Tse TPK, Lam SW, Mak CHK, Chan DTM, Lee MWY, Wong ST, Chan KY, Poon WS.

J Clin Neurosci. 2019 May;63:134-141. doi: 10.1016/j.jocn.2019.01.022. Epub 2019 Jan 31.

PMID:
30712777
11.

Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.

Metellus P, Coulibaly B, Nanni I, Fina F, Eudes N, Giorgi R, Barrie M, Chinot O, Fuentes S, Dufour H, Ouafik L, Figarella-Branger D.

Cancer. 2009 Oct 15;115(20):4783-94. doi: 10.1002/cncr.24546.

12.

Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.

Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, Sabel MC, Herrlinger U, Ketter R, Schlegel U, Marosi C, Reifenberger G, Wick W, Tonn JC, Wirsching HG.

Neuro Oncol. 2016 Apr;18(4):549-56. doi: 10.1093/neuonc/nov326. Epub 2016 Jan 27.

13.

An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity.

Oppenlander ME, Wolf AB, Snyder LA, Bina R, Wilson JR, Coons SW, Ashby LS, Brachman D, Nakaji P, Porter RW, Smith KA, Spetzler RF, Sanai N.

J Neurosurg. 2014 Apr;120(4):846-53. doi: 10.3171/2013.12.JNS13184. Epub 2014 Jan 31.

PMID:
24484232
14.

The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection?

Li YM, Suki D, Hess K, Sawaya R.

J Neurosurg. 2016 Apr;124(4):977-88. doi: 10.3171/2015.5.JNS142087. Epub 2015 Oct 23.

PMID:
26495941
15.

Primary glioblastoma multiforme in younger patients: a single-institution experience.

Ulutin C, Fayda M, Aksu G, Cetinayak O, Kuzhan O, Ors F, Beyzadeoglu M.

Tumori. 2006 Sep-Oct;92(5):407-11.

PMID:
17168433
16.
17.

The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.

Rapp M, Goeppert M, Felsberg J, Steiger HJ, Sabel M.

Br J Neurosurg. 2013 Aug;27(4):430-5. doi: 10.3109/02688697.2013.767317. Epub 2013 Feb 18.

PMID:
23418781
18.

Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O6-Methylguanine DNA Methyltransferase Status in Patients with Glioblastoma.

Sharma M, Bellamkonda S, Mohapatra S, Meola A, Jia X, Mohammadi A, Angelov L, Barnett GH, Vogelbaum M, Ahluwalia MS.

World Neurosurg. 2018 Aug;116:e147-e161. doi: 10.1016/j.wneu.2018.04.134. Epub 2018 Apr 27.

PMID:
29709748
19.

Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection.

Ringel F, Pape H, Sabel M, Krex D, Bock HC, Misch M, Weyerbrock A, Westermaier T, Senft C, Schucht P, Meyer B, Simon M; SN1 study group.

Neuro Oncol. 2016 Jan;18(1):96-104. doi: 10.1093/neuonc/nov145. Epub 2015 Aug 4.

20.

Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article.

Marina O, Suh JH, Reddy CA, Barnett GH, Vogelbaum MA, Peereboom DM, Stevens GH, Elinzano H, Chao ST.

J Neurosurg. 2011 Aug;115(2):220-9. doi: 10.3171/2011.3.JNS10495. Epub 2011 May 6.

PMID:
21548745

Supplemental Content

Support Center